Glanbia to Benefit from Ageing Populations, GLP-1 Weight-Loss Uptake
Dow Jones
Oct 05
1023 GMT - Glanbia has a clear path toward continued market share expansion with organic growth through 2028 above its peer average, Berenberg analysts write. "Glanbia is a leader in AI visibility and brand perception, with its outlook compounded by ongoing structural tailwinds across all three of its businesses," they say. The analysts add that the Irish nutrition company will continue to benefit from ageing populations and GLP-1 weight-loss adoption. Berenberg has a buy rating on the stock and 24.30 euro target price. Shares are down 0.05% at 18.96 euros but 30% higher over the year to date.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.